A federal jury has returned a defense verdict for Mead Johnson in Inman v. Mead Johnson & Company, giving MDL 3026 its first federal jury verdict in the NEC litigation.
Alexis Inman alleged that Mead Johnson's Enfamil Premature Formula contributed to the NEC that killed her son, Daniel Windley, and that the company failed to adequately warn about the risk and should have adopted a safer alternative formulation.
After surviving Daubert challenges, summary judgment and a late preemption challenge, both liability theories reached trial. The jury ultimately rejected Inman's case and returned a verdict for Mead Johnson.
For plaintiff lawyers following the NEC docket, this is a significant defense result. It is also the first actual federal jury data point after the earlier Abbott bellwethers ended before juries could decide liability.
What Did the Jury Reject?
That answer requires some caution.
As of this initial report, a detailed verdict form or juror account has not yet been publicly available. Without it, there is no factual basis to say the jury specifically rejected the epidemiology, Daniel-specific causation, failure to warn, the proposed lactose formulation, or some combination of those issues.
A defense verdict establishes that Inman failed to carry her burden on at least one required element of each theory submitted to the jury. It does not, by itself, tell us which element proved decisive.
That distinction will matter when lawyers begin trying to apply Inman to other NEC cases.
Judge Pallmeyer had previously contemplated special verdict questions identifying causation theories in the event of a plaintiff verdict. Whether today's defense verdict form provides similar insight is one of the first things worth examining once it becomes available.
What Happened Just Before the Verdict
Mead Johnson entered deliberations with one additional motion pending. At the close of evidence Friday, the company renewed its request for judgment as a matter of law under Rule 50, asking Judge Pallmeyer to direct a verdict on both the failure-to-warn and alternative-design claims.
Mead's design argument focused heavily on defense expert Dr. Erika Claud, who testified that research comparing higher- and lower-lactose formulas favored lower lactose because of feeding tolerance. Mead argued that testimony went unrebutted and undermined Inman's contention that a lactose-based Enfamil formulation represented a safer, feasible alternative.
One of the final defense witnesses also gave the jury an interesting contrast. Mead Johnson's nutrition chief continued to defend Enfamil Premature as safe while acknowledging that premature infants receiving formula carry a higher NEC risk than those receiving human breast milk.
Despite that acknowledgment and the corporate evidence presented during trial, the jury was not persuaded to impose liability.
Why This Verdict Matters
Inman carries unusual significance because Mead Johnson itself selected the case as one of its defense-selected bellwethers.
That should be considered when extrapolating today's result across the broader docket. Bellwethers are intended to provide information, not determine hundreds of other cases, and the medical history, feeding chronology, treating physicians, and causation evidence can vary substantially from claimant to claimant.
Still, the defense now has something it did not have before today: a federal jury verdict rejecting liability after hearing a fully developed NEC case.
Plaintiffs, meanwhile, can point to a litigation landscape that remains mixed. Abbott recently agreed to approximately $670 million in payments resolving the Gill judgment and NEC claims involving roughly 2,000 additional infants, while state-court NEC litigation has produced both plaintiff and defense results.
Today's verdict does not resolve that conflict. It does make the first federal jury signal a defense win.
Atraxia Media is reviewing the verdict form and any post-verdict comments from counsel and will report what the jury's answers reveal as soon as they become available.